GO:0006048 UDP-N-acetylglucosamine biosynthetic process: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006048 describes the biochemical reactions that produce UDP-N-acetylglucosamine (UDP-GlcNAc), a key nucleotide-sugar donor for glycosylation and cell wall synthesis [1,4].
• The pathway integrates nutrient sensing, energy metabolism, and biosynthetic demands, linking it to macrophage polarization and pluripotency [1,3].
• Key enzymes include GFAT, GNA1, and UAP1 in eukaryotes, and MurB in bacteria; their activities are regulated by feedback inhibition and kinase signaling [4,5].
• UDP-GlcNAc biosynthesis supports hyaluronan synthesis and extracellular matrix production, impacting cancer and inflammation [6,7].
• Dysregulation of UDP-GlcNAc metabolism is implicated in immune evasion, developmental defects, and microbial pathogenesis [2,8].
• CRISPR-based models (KO, point mutation, knock-in, overexpression) enable precise dissection of gene function in this pathway.
Description
UDP-N-acetylglucosamine (UDP-GlcNAc) is a central metabolite in glycosylation, serving as the donor substrate for O-GlcNAcylation, N-glycosylation, and glycosaminoglycan synthesis [1,6]. The biosynthetic process that generates UDP-GlcNAc, annotated as GO:0006048, is a conserved metabolic module that converts fructose-6-phosphate and glutamine into this essential nucleotide-sugar. Understanding this pathway is critical because it connects cellular energy status, nutrient availability, and biosynthetic demands to diverse physiological outputs, including immune cell function and stem cell pluripotency [1,3]. Recent studies have highlighted that UDP-GlcNAc biosynthesis is not merely a housekeeping function but a regulated node that influences macrophage polarization and cancer immune evasion [1,2]. For example, oxidative phosphorylation safeguards pluripotency via UDP-GlcNAc, demonstrating a direct link between mitochondrial metabolism and stem cell identity. In Saccharomyces cerevisiae, the Ngk1 kinase promotes UDP-GlcNAc biosynthesis by regulating N-acetylglucosamine metabolism, revealing a signaling axis that adjusts flux through this pathway. Given its broad impact, researchers are increasingly targeting UDP-GlcNAc biosynthetic enzymes for therapeutic intervention and as biomarkers. This article provides a comprehensive overview of the pathway, its genetic components, regulatory mechanisms, and experimental strategies, with a focus on CRISPR-based models for functional genomics.
UDP-N-acetylglucosamine biosynthetic process At A Glance
| GO ID | GO:0006048 |
|---|---|
| GO term | UDP-N-acetylglucosamine biosynthetic process |
| Ontology | biological_process |
| Synonym | UDP-GlcNAc biosynthesis; UDP-N-acetylglucosamine anabolism; UDP-N-acetylglucosamine formation |
| Major function | Production of UDP-GlcNAc for glycosylation, cell wall synthesis, and signaling |
| Key enzymes | GFAT, GNA1, UAP1, MurB (bacteria) |
| Pathway location | Cytosol (eukaryotes); cytoplasm (prokaryotes) |
| Regulation | Feedback inhibition by UDP-GlcNAc; kinase signaling (e.g., Ngk1) |
| Disease relevance | Cancer immune evasion, pluripotency, microbial pathogenesis [2,3,5] |
What Is GO:0006048?
GO:0006048, UDP-N-acetylglucosamine biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of UDP-N-acetylglucosamine, a substance composed of N-acetylglucosamine in glycosidic linkage with uridine diphosphate. This process encompasses the enzymatic steps that convert simple precursors into the activated nucleotide-sugar, which is essential for various glycosylation reactions.
Why Is UDP-N-acetylglucosamine biosynthetic process Important in Cell Biology?
UDP-N-acetylglucosamine biosynthesis is a metabolic hub that integrates nutrient sensing with essential cellular processes such as protein glycosylation, cell wall assembly, and signaling. Its dysregulation has been linked to cancer progression, immune evasion, and developmental disorders, making it a promising target for therapeutic intervention and a critical area for basic and translational research [1,2,3].
• Provides UDP-GlcNAc for O-GlcNAcylation, a dynamic post-translational modification that regulates signaling and transcription.
• Supports N-glycosylation and glycosaminoglycan synthesis, impacting cell surface interactions and matrix remodeling [6,7].
• Modulates macrophage polarization, with metabolic modules including UDP-GlcNAc biosynthesis influencing inflammatory responses.
• Links oxidative phosphorylation to pluripotency maintenance in stem cells.
• Contributes to cancer immune evasion through PD-L1 up-regulation in a folate cycle-dependent manner.
• Essential for bacterial cell wall synthesis, as MurB is a validated antibiotic target.
• Regulated by Ngk1 kinase in yeast, highlighting conserved signaling control.
• Involved in hyaluronan synthesis, which is critical for tissue homeostasis and cancer metastasis [6,7].
• Dysregulated in protozoan parasites like Giardia intestinalis, affecting host-pathogen interactions.
What Happens During UDP-N-acetylglucosamine biosynthetic process?
Conversion of Fructose-6-Phosphate to Glucosamine-6-Phosphate
In simple terms: The pathway starts by converting a sugar phosphate into a amino sugar phosphate.
The first committed step is catalyzed by glutamine:fructose-6-phosphate amidotransferase (GFAT), which transfers an amino group from glutamine to fructose-6-phosphate, yielding glucosamine-6-phosphate and glutamate. This reaction is rate-limiting and subject to feedback inhibition by UDP-GlcNAc [1,4].
Acetylation and Isomerization to N-Acetylglucosamine-6-Phosphate
In simple terms: The amino sugar is then acetylated and rearranged to form a key intermediate.
Glucosamine-6-phosphate is acetylated by glucosamine-6-phosphate N-acetyltransferase (GNA1) to N-acetylglucosamine-6-phosphate, which is subsequently isomerized to N-acetylglucosamine-1-phosphate by phosphoacetylglucosamine mutase (AGM1). These steps prepare the sugar for activation with UTP.
Activation to UDP-N-acetylglucosamine
In simple terms: The intermediate is linked to a nucleotide carrier to become the final product.
UDP-N-acetylglucosamine pyrophosphorylase (UAP1) catalyzes the transfer of uridine monophosphate from UTP to N-acetylglucosamine-1-phosphate, releasing pyrophosphate and forming UDP-N-acetylglucosamine. This activated nucleotide-sugar is the substrate for glycosyltransferases [1,6].
Bacterial Pathway and MurB
In simple terms: Bacteria use a similar but distinct route involving MurB to make a cell wall precursor.
In bacteria, UDP-N-acetylglucosamine is synthesized and then converted to UDP-N-acetylmuramic acid by MurA and MurB. MurB catalyzes the reduction of UDP-N-acetylglucosamine-enolpyruvate to UDP-N-acetylmuramic acid, a key step in peptidoglycan biosynthesis. The crystal structure of MurB from Mycobacterium tuberculosis has been solved, aiding drug design.
Regulation by Ngk1 Kinase in Yeast
In simple terms: A kinase enzyme can boost the pathway by controlling sugar metabolism.
In Saccharomyces cerevisiae, Ngk1 kinase phosphorylates and regulates N-acetylglucosamine metabolism, promoting UDP-GlcNAc biosynthesis. This signaling mechanism allows yeast to adapt to nutrient availability and cell wall stress.
Key Genes Involved in GO:0006048 UDP-N-acetylglucosamine biosynthetic process
The following genes and proteins are central to UDP-N-acetylglucosamine biosynthesis across species, with roles in catalysis, regulation, and downstream utilization.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GFAT1 (GFPT1) | Catalyzes first committed step; rate-limiting | Target for metabolic regulation; linked to diabetes and cancer |
| GFAT2 (GFPT2) | Isoform of GFAT; tissue-specific | Potential role in insulin resistance and cancer |
| GNA1 | Acetylates glucosamine-6-phosphate | Essential for UDP-GlcNAc synthesis; studied in yeast |
| AGM1 (PAGM1) | Isomerizes GlcNAc-6-P to GlcNAc-1-P | Mutations cause developmental disorders |
| UAP1 | Synthesizes UDP-GlcNAc from GlcNAc-1-P and UTP | Key enzyme for glycosylation; target in cancer |
| MurA | Bacterial enzyme; transfers enolpyruvate to UDP-GlcNAc | Antibiotic target; essential for cell wall |
| MurB | Reduces enolpyruvate to D-lactate in UDP-MurNAc | Validated drug target in M. tuberculosis |
| Ngk1 | Kinase that promotes UDP-GlcNAc biosynthesis | Regulatory node in yeast; potential antifungal target |
| O-GlcNAc transferase (OGT) | Uses UDP-GlcNAc for protein O-GlcNAcylation | Links metabolism to signaling; cancer and neurodegeneration |
| HAS1/2/3 | Hyaluronan synthases; utilize UDP-GlcNAc and UDP-GlcA | Matrix remodeling; cancer and inflammation [6,7] |
| MTHFD2 | Folate cycle enzyme; supports UDP-GlcNAc synthesis | Immune evasion via PD-L1; cancer target |
| GFPT1 | Glutamine--fructose-6-phosphate transaminase 1 | Congenital myasthenic syndrome; metabolic disorders |
| UAP1L1 | UAP1-like protein; potential pseudogene | Unknown function; may regulate UDP-GlcNAc levels |
| PGM3 | Phosphoglucomutase 3; involved in GlcNAc-1-P synthesis | Immunodeficiency; glycosylation defects |
| NAGK | N-acetylglucosamine kinase; salvage pathway | Alternative route for UDP-GlcNAc synthesis |
| GNPNAT1 | Glucosamine-phosphate N-acetyltransferase 1 | Same as GNA1; essential for pathway |
| UDP-GlcNAc 4'-epimerase | Interconverts UDP-GlcNAc and UDP-GalNAc | Giardia lacks UDP-glucose epimerase activity |
| Hyaluronan synthase (HAS) | Polymerizes hyaluronan using UDP-GlcNAc | Direct link to matrix biology [6,7] |
How Is UDP-N-acetylglucosamine biosynthetic process Regulated?
UDP-N-acetylglucosamine biosynthesis is regulated at multiple levels. The rate-limiting enzyme GFAT is feedback-inhibited by UDP-GlcNAc and subject to transcriptional control by nutrient-sensing pathways. In yeast, Ngk1 kinase promotes the pathway by regulating N-acetylglucosamine metabolism, linking environmental signals to flux. Additionally, oxidative phosphorylation supports pluripotency by maintaining UDP-GlcNAc levels, suggesting mitochondrial regulation. The folate cycle enzyme MTHFD2 also contributes to UDP-GlcNAc synthesis, influencing immune evasion.
UDP-N-acetylglucosamine biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GFPT1 | Congenital myasthenic syndrome; metabolic disorders | Knockout or point mutation in cell lines; patient-derived iPSCs |
| MTHFD2 | Cancer immune evasion via PD-L1 | Knockout in melanoma or lung cancer cells; syngeneic mouse models |
| PGM3 | Immunodeficiency with glycosylation defects | Knock-in of patient mutations in HEK293 or T cells |
| MurB | Tuberculosis; bacterial cell wall synthesis | Knockout in M. tuberculosis; enzymatic assays |
| UDP-GlcNAc 4'-epimerase | Giardiasis; cyst wall formation | Knockout in Giardia; biochemical characterization |
Cancer and Immune Evasion
UDP-N-acetylglucosamine biosynthesis supports cancer cell glycosylation and immune evasion. MTHFD2, a folate cycle enzyme, induces PD-L1 up-regulation through UDP-GlcNAc-dependent mechanisms, promoting immune escape in cancer. Hyaluronan synthesis, which depends on UDP-GlcNAc, is linked to tumor progression and metastasis [6,7].
Metabolic and Developmental Disorders
Defects in UDP-GlcNAc biosynthesis cause congenital disorders of glycosylation. Mutations in GFPT1 lead to congenital myasthenic syndrome, while PGM3 deficiency results in immunodeficiency with glycosylation defects [1,4]. These highlight the pathway's importance in human development and immune function.
Infectious Diseases
Bacterial pathogens require UDP-N-acetylglucosamine for cell wall synthesis. MurB is essential in Mycobacterium tuberculosis, making it a target for antibiotics. In protozoan parasites like Giardia intestinalis, a unique UDP-GlcNAc 4'-epimerase supports cyst wall formation, offering a potential drug target.
Stem Cell Pluripotency and Regeneration
Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine, linking metabolism to stem cell identity. This connection suggests that modulating UDP-GlcNAc levels could influence regenerative therapies.
From UDP-N-acetylglucosamine biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GFAT1 loss affect UDP-GlcNAc levels and glycosylation? | CRISPR knockout in HEK293 or cancer cell lines |
| How do point mutations in UAP1 alter enzyme kinetics? | CRISPR point mutation knock-in in isogenic cell lines |
| Can tagging endogenous GFAT1 reveal its localization? | Knock-in of fluorescent tag (e.g., GFP) at GFAT1 locus |
| What is the effect of MTHFD2 overexpression on PD-L1? | Overexpression via lentiviral transduction in cancer cells |
| Which genes regulate UDP-GlcNAc biosynthesis in yeast? | CRISPR library screening in S. cerevisiae |
| Does Ngk1 kinase regulate UDP-GlcNAc flux? | Knockout and point mutation in yeast; metabolomics |
How to Study the UDP-N-acetylglucosamine biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | UDP-GlcNAc and intermediate levels | Quantify pathway flux in cells |
| 13C tracing | Carbon flux through hexosamine pathway | Determine metabolic rewiring in cancer |
| O-GlcNAc immunoblotting | Protein O-GlcNAcylation | Assess downstream effects of UDP-GlcNAc |
| CRISPR knockout screens | Gene essentiality and pathway regulators | Identify synthetic lethal targets |
| X-ray crystallography | Enzyme structure and inhibitor binding | Drug design for MurB or GFAT |
| RNA-seq | Transcriptional changes in pathway genes | Evaluate regulatory mechanisms |
| Hyaluronan ELISA | Hyaluronan production | Link UDP-GlcNAc to matrix synthesis |
Metabolomics and Flux Analysis
Liquid chromatography-mass spectrometry (LC-MS) can quantify UDP-GlcNAc and intermediates. Stable isotope tracing with 13C-glucose or 15N-glutamine reveals flux through the pathway [1,4].
Glycosylation Profiling
Lectins and mass spectrometry can assess O-GlcNAcylation and N-glycosylation status, providing functional readouts of UDP-GlcNAc availability [1,6].
CRISPR Screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate UDP-GlcNAc levels or sensitivity to glycosylation inhibitors [2,4].
Structural Biology
X-ray crystallography and cryo-EM of enzymes like MurB and GFAT provide mechanistic insights and aid inhibitor design.
How CRISPR Can Be Used to Study GO:0006048 UDP-N-acetylglucosamine biosynthetic process
Knockout
CRISPR knockout of GFAT1, UAP1, or GNA1 abolishes UDP-GlcNAc biosynthesis, causing glycosylation defects and growth arrest. These models are used to study pathway essentiality and compensatory mechanisms [1,4].
Point Mutation
Introducing patient-derived point mutations (e.g., in GFPT1 or PGM3) via CRISPR knock-in allows functional analysis of enzyme variants and their impact on UDP-GlcNAc levels [1,4].
Knock-in
Tagging endogenous enzymes with fluorescent or affinity tags (e.g., GFP, HA) enables live-cell imaging and proteomics to study localization and interactions.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of GFAT1, UAP1, or MTHFD2 increases UDP-GlcNAc flux, useful for studying downstream effects like PD-L1 up-regulation.
How EDITGENE Supports UDP-N-acetylglucosamine biosynthetic process Research
Researchers studying UDP-N-acetylglucosamine biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or therapeutic response. Precise genetic models are essential to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for UDP-N-acetylglucosamine biosynthetic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GNPDA1 Knockout HEK293 Cell Line | EDJ-KQ2060 | Human | 10007 | Details Get a Quote |
| GFPT1 Knockout HEK293 Cell Line | EDJ-KQ4700 | Human | 2673 | Details Get a Quote |
| UAP1 Knockout HEK293 Cell Line | EDJ-KQ5829 | Human | 6675 | Details Get a Quote |
| GFPT2 Knockout HEK293 Cell Line | EDJ-KQ6193 | Human | 9945 | Details Get a Quote |
| GNPDA2 Knockout HEK293 Cell Line | EDJ-KQ9303 | Human | 132789 | Details Get a Quote |
| UAP1L1 Knockout HEK293 Cell Line | EDJ-KQ10726 | Human | 91373 | Details Get a Quote |
| GNPNAT1 Knockout HEK293 Cell Line | EDJ-KQ13618 | Human | 64841 | Details Get a Quote |
| NAGK Knockout HEK293 Cell Line | EDJ-KQ14365 | Human | 55577 | Details Get a Quote |
| GNPDA1 Knockout A-549 Cell Line | EDJ-KQ22126 | Human | 10007 | Details Get a Quote |
| GNPDA1 Knockout HCT 116 Cell Line | EDJ-KQ22127 | Human | 10007 | Details Get a Quote |
| GNPDA1 Knockout HeLa Cell Line | EDJ-KQ22128 | Human | 10007 | Details Get a Quote |
| GFPT1 Knockout A-549 Cell Line | EDJ-KQ26171 | Human | 2673 | Details Get a Quote |
| GNPDA2 Knockout HCT 116 Cell Line | EDJ-KQ35917 | Human | 132789 | Details Get a Quote |
| GNPDA2 Knockout HeLa Cell Line | EDJ-KQ35918 | Human | 132789 | Details Get a Quote |
| UAP1L1 Knockout HCT 116 Cell Line | EDJ-KQ36997 | Human | 91373 | Details Get a Quote |
Displaying Records 1 To 15 Of 36 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About UDP-N-acetylglucosamine biosynthetic process
What is UDP-N-acetylglucosamine biosynthetic process?
It is the metabolic pathway (GO:0006048) that produces UDP-GlcNAc, a nucleotide-sugar used in glycosylation and cell wall synthesis [1,4].
What genes are involved in UDP-N-acetylglucosamine biosynthesis?
Key genes include GFAT1, GNA1, AGM1, UAP1 in eukaryotes, and MurA/MurB in bacteria [1,4,5].
How is UDP-N-acetylglucosamine biosynthesis regulated?
It is regulated by feedback inhibition of GFAT by UDP-GlcNAc, kinase signaling (e.g., Ngk1), and mitochondrial metabolism [1,3,4].
Why is UDP-GlcNAc important for cancer?
UDP-GlcNAc supports glycosylation of immune checkpoint proteins like PD-L1, contributing to immune evasion.
What diseases are linked to UDP-N-acetylglucosamine biosynthesis?
Congenital myasthenic syndrome, immunodeficiency, cancer, and bacterial infections [1,2,4,5].
How can I study UDP-N-acetylglucosamine biosynthesis using CRISPR?
Use knockout, point mutation, knock-in, or overexpression models to manipulate pathway genes and assess effects on glycosylation and metabolism [1,4].
What is the role of MurB in UDP-GlcNAc biosynthesis?
MurB catalyzes a step in bacterial cell wall synthesis, converting UDP-GlcNAc-enolpyruvate to UDP-MurNAc.
Does oxidative phosphorylation affect UDP-GlcNAc?
Yes, oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine, linking energy metabolism to stem cell identity.
Which methods measure UDP-GlcNAc levels?
LC-MS metabolomics, stable isotope tracing, and glycosylation profiling [1,4].
What CRISPR services does EDITGENE offer for this pathway?
Knockout, point mutation, knock-in, overexpression cell models, library screening, and bioinformatics [1,2,4].
Conclusion
UDP-N-acetylglucosamine biosynthesis (GO:0006048) is a fundamental metabolic pathway with far-reaching implications for glycosylation, cell signaling, and disease. Its integration with energy metabolism and immune regulation underscores its potential as a therapeutic target. Advances in CRISPR technology and metabolomics provide powerful tools to dissect this pathway and translate findings into clinical applications.
References
- 1. Jha AK et al.. 2015. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization.. Immunity 42(3):419-30 PMID: 25786174
- 2. Shang M et al.. 2021. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.. Nat Commun 12(1):1940 PMID: 33782411
- 3. Cao J et al.. 2023. Oxidative phosphorylation safeguards pluripotency via UDP-N-acetylglucosamine.. Protein Cell 14(5):376-381 PMID: 37155316
- 4. Nishikawa A et al.. 2024. Ngk1 kinase-mediated N-acetylglucosamine metabolism promotes UDP-GlcNAc biosynthesis in Saccharomyces cerevisiae.. FEBS Lett 598(13):1644-1654 PMID: 38622055
- 5. Eniyan K et al.. 2018. Crystal structure of UDP-N-acetylglucosamine-enolpyruvate reductase (MurB) from Mycobacterium tuberculosis.. Biochim Biophys Acta Proteins Proteom 1866(3):397-406 PMID: 29203374
- 6. Caon I et al.. 2021. Cell Energy Metabolism and Hyaluronan Synthesis.. J Histochem Cytochem 69(1):35-47 PMID: 32623953
- 7. Vigetti D et al.. 2014. Metabolic control of hyaluronan synthases.. Matrix Biol 35:8-13 PMID: 24134926
- 8. Lopez AB et al.. 2007. UDP-N-acetylglucosamine 4'-epimerase from the intestinal protozoan Giardia intestinalis lacks UDP-glucose 4'-epimerase activity.. J Eukaryot Microbiol 54(2):154-60 PMID: 17403156
